AmWeb: A novel interactive web tool for antimicrobial resistance surveillance, applicable to both community and hospital patients

Dean Ironmonger*, Obaghe Edeghere, Savita Gossain, Amardeep Bains, Peter M. Hawkey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Background:Antimicrobial resistance (AMR) is recognized as one of the most significant threats to human health. Local and regionalAMRsurveillance enables the monitoring of temporal changes in susceptibility to antibiotics and can provide prescribing guidance to healthcare providers to improve patient management and help slow the spread of antibiotic resistance in the community. There is currently a paucity of routine community-level AMR surveillance information. Methods:The HPA in England sponsored the development of an AMR surveillance system (AmSurv) to collate local laboratory reports. In theWest Midlands region of England, routine reporting of AMR data has been established via the AmSurv systemfromall diagnostic microbiology laboratories. TheHPARegional Epidemiology Unit developed a web-enabled database application (AmWeb) to provide microbiologists, pharmacists and other stakeholders with timely access to AMR data using user-configurable reporting tools.Results: AmWebwas launched in theWest Midlands in January 2012 and is used by microbiologists and pharmacists to monitor resistance profiles, perform local benchmarking and compile data for infection control reports. AmWeb is now being rolled out to all English regions. Conclusions:It is expected thatAmWebwillbecomeavaluable tool for monitoring the threat fromnewlyemerging or currently circulating resistant organisms and helping antibiotic prescribers to select the best treatment options for their patients.

Original languageEnglish
Article numberdkt181
Pages (from-to)2406-2413
Number of pages8
JournalJournal of Antimicrobial Chemotherapy
Issue number10
Publication statusPublished - Oct 2013

Bibliographical note

Funding Information:
P. M. H. has received honoraria for developing and delivering educational presentations for Eumedica, Pfizer, Merck, Novartis, Magus Communications and Wyeth and received research funding from Pfizer, Eumedica; consultancy for Pfizer, Novartis, Basilea, Novacta, Novolytics, Merck, Wyeth and Optimer. He is a director of ModusMedica, a medical education company. All other authors: none to declare.

Funding Information:
This work was supported by the HPA.


  • Antibiotics
  • Health informatics
  • Microbiology


Dive into the research topics of 'AmWeb: A novel interactive web tool for antimicrobial resistance surveillance, applicable to both community and hospital patients'. Together they form a unique fingerprint.

Cite this